ML models trained on longitudinal data may adjust follow-up frequency dynamically; low-risk patients (i.e., those with stable lesions with favorable biomarkers) transition to extended 6–12-month intervals, while high-risk groups (NSCLC with EGFR wild-type or rapid pre-treatment progression) undergo 3-month scans with multiparametric sequences [140,159]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.